Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid

BACKGROUND: Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15–19% of cases. Peritonea...

Descripción completa

Detalles Bibliográficos
Autores principales: Roussel-Simonin, Cyril, Blanc-Durand, Felix, Tang, Roseline, Vasseur, Damien, Le Formal, Audrey, Chardin, Laure, Yaniz, Elisa, Gouy, Sébastien, Maulard, Amandine, Scherier, Stéphanie, Sanson, Claire, Lacroix, Ludovic, Cotteret, Sophie, Mauny, Lea, Zaccarini, François, Rouleau, Etienne, Leary, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626673/
https://www.ncbi.nlm.nih.gov/pubmed/37932736
http://dx.doi.org/10.1186/s12943-023-01864-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626673/
https://www.ncbi.nlm.nih.gov/pubmed/37932736
http://dx.doi.org/10.1186/s12943-023-01864-1

Ejemplares similares